Icon Plc(ICLR) Price Forecast & Company Analysis. P/E · Dividend · Earnings · Price Target · RSI · MACD | US Stocks Today
Full metrics table
| Index | - | P/E | 332.15 | EPS (ttm) | 0.55 | Insider Own | 1.05% | Shs Outstand | 77.2M | Perf Week | 5.05% |
| Market Cap | 14.12B | Forward P/E | 15.48 | EPS next Y | 11.87% | Insider Trans | -2.88% | Shs Float | 76.3M | Perf Month | 4.22% |
| Enterprise Value | 16.72B | PEG | 7.82 | EPS next Q | 2.87 | Inst Own | 104.79% | Short Float | 3.89% | Perf Quarter | 2.69% |
| Income | 0.04B | P/S | 1.7 | EPS this Y | -15.69% | Inst Trans | 0.22% | Short Ratio | 3.43 | Perf Half Y | 78.53% |
| Sales | 8.29B | P/B | 1.51 | EPS next 5Y | 1.98% | ROA | 0.26% | Short Interest | 2.97M | Perf YTD | 0.42% |
| Book/sh | 121.55 | P/C | 15.21 | EPS past 3/5Y | -22.33% -14.31% | ROE | 0.45% | 52W High | -10.26% ($203.91) | Perf Year | 0.52% |
| Cash/sh | 12.03 | P/FCF | 15.79 | Sales past 3/5Y | 2.15% 24.15% | ROIC | 0.37% | 52W Low | 174.87% ($66.57) | Perf 3Y | -22.24% |
| Dividend Est. | - | EV/EBITDA | 13.41 | EPS Y/Y TTM | -94.18% | Gross Margin | 19.45% | Volatility(W/M) | 5.04% 4.74% | Perf 5Y | -35.05% |
| Dividend TTM | - | EV/Sales | 2.02 | Sales Y/Y TTM | 2.08% | Oper. Margin | 10.14% | ATR (14) | 7.73 | Perf 10Y | 127.36% |
| Dividend Ex-Date | - | Quick Ratio | 0.95 | EPS Q/Q | -63.33% | Profit Margin | 0.51% | RSI (14) | 62.13 | Recom | 2.05 |
| Dividend Gr. 3/5Y | - | Current Ratio | 0.95 | Sales Q/Q | 1.2% | SMA20 | 6.86% ($171.23) | Beta | 1.22 | Target Price | $190.31 |
| Payout | - | Debt/Eq | 0.38 | Earnings | 2026/10/27 | SMA50 | 8% ($169.43) | Rel Volume | 1.03 | Prev Close | $183.78 |
| Employees | 40100 | LT Debt/Eq | 0.24 | EPS/Sales Surpr. | 1.65% 0.61% | SMA200 | 25.9% ($145.34) | Avg Volume(3M) | 0.87M | Price | $182.98 |
| IPO | 1998/5/15 | Option/Short | Yes/Yes | Trades | 13028 | Volume | 890,783 | Change | -0.44% |
Headquartered in Ireland, this global contract research organization (CRO) conducts and manages clinical trials of new drugs for pharmaceutical and biotech companies, while providing related data and laboratory services. Its business is underpinned by outsourcing demand for new drug development.
Over the past 1 year, on the higher side
10% below its 1-year high.
Traded about as much as usual. That is 103% of its average volume.
ICLR has weak earning power
After all costs, only $0.51 of every $100 in sales is left.
Tap to view numbers
Growth has stalled
Earnings are expected to grow by -15.7% this year.
Tap to view numbers
The price is about the industry average
For a company expected to earn $100 next year, you would pay $1,548. Peers typically go for $2,775. Compared with its own 5-year average, it is 701% pricier now.
Tap to view numbers
Results came in about as expected
Mixed beats and misses
Tap to view numbers
Opinions on the outlook are split
Analyst sentiment is Buy.
Tap to view numbers
Holding long would have lost money
Bought 5 years ago, your return today would be -35.0%. The S&P 500 did +70% over the same period.
Tap to view numbers
No dividend
It reinvests profits in the business instead of paying dividends.
Ownership looks stable
Institutions hold 104.8%.
Tap to view numbers
Multiple ETFs hold this stock
Buying this ETF gives you exposure to this stock as well.
It ranks #16 of 44 in the industry
Based on market cap of $14B.
FAQ
What kind of company is ICLR?
ICLR belongs to the Healthcare sector and operates in the Diagnostics & Research industry.
What is the market cap of ICLR?
The market cap of ICLR is approximately $14.1B, ranking 743 within its sector.
What is the P/E ratio of ICLR?
ICLR has a P/E ratio of approximately 332.1x, which can be used to assess its valuation relative to the Healthcare sector average.
What is the 52-week high and low for ICLR?
ICLR has recorded a 52-week high of $203.91 and a low of $66.57.
